Hyphens Pharma International Ltd. · SGX:1J5
Hyphens Pharma International — FY2023 Earnings Presentation
18 slides from Hyphens Pharma International's earnings presentation, Mar 7, 2024
Slide 1: Results Briefing FY2023
HYPHENS PHARMA INTERNATIONAL LIMITED RESULTS BRIEFING FY2023 7 MARCH 2024
Slide 2: Disclaimer
DISCLAIMER • This presentation has been prepared by Hyphens Pharma International Limited (the "Company" and, together with its subsidiaries, the "Group"). • This content in this presentation is being furnished to you on a confidential basis and solely for your information and neither this presentati
Slide 3: Agenda
AGENDA 01 Overview 02 Our Business 03 Financial Results 04 Commitment to Sustainability 05 Business Outlook
Slide 4: Overview
01 OVERVIEW • OUTLOOK 2024: 170.6 m 95.9 m ambitious growth targets driven by FY2023 Revenue (SGD) +5.1% YoY 2H2023 Revenue (SGD) +28.4% HoH + deeper product penetration + new market entries 8.6 m 5.1 m + product margin optimisation FY2023 PAT (SGD) -24.6% YoY 2H2023 PAT (SGD) +45.7% HoH + new growt
Slide 5: Our Business
02 OUR BUSINESS A leading ASEAN’s Specialty Pharma and Consumer Healthcare Group
Slide 6: Segments and Presence
SEGMENTS AND PRESENCE Specialty Pharma Proprietary Medical Hypermart Principals Brands and Digital 25% Revenue 102.2m 25.7m 42.7m SGD 60% 15% 2% 28% Others , 11% EBITDA 9.5m 3.8m 0.2m Malaysia SGD , 10% Singapore , 50% 70% Vietnam , Sales contribution 29% FY2023 EBITDA 9% 15% 1% Margin 5 14 >9000 Om
Slide 7: Latest Updates
LATEST UPDATES Partner with 7-Eleven to Successful registration Acquisition of Ardence offer Ocean Health® of Nabota® in Malaysia Pharma Sdn Bhd supplements Official launch of Nabota ® and Plinest in Singapore Ceradan® enters 5 major Middle East markets Establishment of Ardence Aesthetics Pte. Ltd.
Slide 8: Financial Results
03 FINANCIAL RESULTS Strengthened Topline Recovery, while continue To Focus On Margin Maximization And Operational Excellence
Slide 9: Overall Performance
OVERALL PERFORMANCE Revenue Profit after tax SGDm +5.1% YoY SGDm -24.6% YoY 120.0 +28.4% HoH 7.0 6.2 +45.7% HoH 95.9 6.0 100.0 5.2 5.1 80.7 81.6 5.0 80.0 74.7 4.2 61.5 63.8 62.1 4.0 60.4 60.6 3.5 3.4 3.5 60.0 54.8 3.1 3.0 2.5 40.0 2.0 1.0 20.0 1.0 - - 1H2019 2H2019 1H2020 2H2020 1H2021 2H2021 1H2022
Slide 10: Performance by Segment
PERFORMANCE BY SEGMENT Revenue(SGDm) ✓ Strong recovery in 2H2023 stems from: 60.0 o improved supply chain situation for 50.0 major selling products 11.2 o strong organic growth from 40.0 7.1 10.9 10.5 10.6 10.7 Ceradan® and Ocean Health® 10.8 11.0 30.0 o inorganic growth from acquisition of 7.2 10.3
Slide 11: Income Statement
INCOME STATEMENT SGDm 2H2023 1H2023 HoH % FY2023 FY2022 YoY % ✓ Strong recovery from the loss of Revenue 95.9 74.7 28% 170.6 162.3 5% Biosensor sales since 1H2023 ✓ Narrowing gross margin due to Gross profit 33.9 28.0 21% 62.0 62.8 -1% Operating costing pressure from principals that expenses (28.1)
Slide 12: Commitment to Sustainability
04 COMMITMENT TO SUSTAINABLITY Preserving Health, Sustaining Tomorrow
Slide 13: Our Commitments to Sustainability
OUR COMMITMENTS TO SUSTAINABILITY Customer Health and Safety Packaging waste Talent Management We’re proud to be awarded Best Partner for 440 20% 129 People and Planet by our principal Chiesi full time increase in new hires employee headcount in FY2023 YoY Corporate Governance 67% 65% 1,625 Our goal
Slide 14: Business Outlook
05 BUSINESS OUTLOOK Ride On The Momentum Of 2H Recovery, Forge Ahead A New Growth Horizon
Slide 15: Business Outlook
BUSINESS OUTLOOK Medical Hypermart and Proprietary Brands Specialty Pharma Portfolio Digital Record FY2024 full year impact from To unlock brand equity value and DocMed records full year revenue in sales of products from Laboratoires grow its presence Malaysia and Vietnam Gilbert S.A.S., Plinest and
Slide 16: New Growth Horizon
NEW GROWTH HORIZON The Medical Aesthetic business of Hyphens Group will be carried out under the brand Ardence, under the leadership of Hyphens Group COO and Ardence Aesthetics CEO, Mr. Yann Alain Marche and Ardence Aesthetics Commercial Director, Mr. Sean Loo. Hyphens Group COO, Ardence Aesthetics
Slide 17: Q&A
Q&A
Slide 18: Thank You
THANK YOU Hyphens Pharma International Limited (SGX: 1J5) 16 Tai Seng Street, Level 4, Singapore 534138 www.hyphensgroup.com
Hyphens Pharma International — FY2023 Earnings Presentation on 6ix